Attacking malignant cells that survive therapy: Exploiting immunogenic modulation

We have recently defined “immunogenic modulation,” a mechanism whereby malignant cells that survive anticancer therapy, due to sublethal delivery or development of treatment resistance, become nonetheless more sensitive to killing by cytotoxic T lymphocytes. This mechanism can be exploited to identi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hodge, James W, Kwilas, Anna, Ardiani, Andressa, Gameiro, Sofia R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902115/
https://www.ncbi.nlm.nih.gov/pubmed/24498561
http://dx.doi.org/10.4161/onci.26937
_version_ 1782300948566114304
author Hodge, James W
Kwilas, Anna
Ardiani, Andressa
Gameiro, Sofia R
author_facet Hodge, James W
Kwilas, Anna
Ardiani, Andressa
Gameiro, Sofia R
author_sort Hodge, James W
collection PubMed
description We have recently defined “immunogenic modulation,” a mechanism whereby malignant cells that survive anticancer therapy, due to sublethal delivery or development of treatment resistance, become nonetheless more sensitive to killing by cytotoxic T lymphocytes. This mechanism can be exploited to identify which therapies will best synergize with immunotherapy, potentially maximizing patient clinical benefit.
format Online
Article
Text
id pubmed-3902115
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-39021152014-02-04 Attacking malignant cells that survive therapy: Exploiting immunogenic modulation Hodge, James W Kwilas, Anna Ardiani, Andressa Gameiro, Sofia R Oncoimmunology Author's View We have recently defined “immunogenic modulation,” a mechanism whereby malignant cells that survive anticancer therapy, due to sublethal delivery or development of treatment resistance, become nonetheless more sensitive to killing by cytotoxic T lymphocytes. This mechanism can be exploited to identify which therapies will best synergize with immunotherapy, potentially maximizing patient clinical benefit. Landes Bioscience 2013-12-01 2013-11-06 /pmc/articles/PMC3902115/ /pubmed/24498561 http://dx.doi.org/10.4161/onci.26937 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Hodge, James W
Kwilas, Anna
Ardiani, Andressa
Gameiro, Sofia R
Attacking malignant cells that survive therapy: Exploiting immunogenic modulation
title Attacking malignant cells that survive therapy: Exploiting immunogenic modulation
title_full Attacking malignant cells that survive therapy: Exploiting immunogenic modulation
title_fullStr Attacking malignant cells that survive therapy: Exploiting immunogenic modulation
title_full_unstemmed Attacking malignant cells that survive therapy: Exploiting immunogenic modulation
title_short Attacking malignant cells that survive therapy: Exploiting immunogenic modulation
title_sort attacking malignant cells that survive therapy: exploiting immunogenic modulation
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902115/
https://www.ncbi.nlm.nih.gov/pubmed/24498561
http://dx.doi.org/10.4161/onci.26937
work_keys_str_mv AT hodgejamesw attackingmalignantcellsthatsurvivetherapyexploitingimmunogenicmodulation
AT kwilasanna attackingmalignantcellsthatsurvivetherapyexploitingimmunogenicmodulation
AT ardianiandressa attackingmalignantcellsthatsurvivetherapyexploitingimmunogenicmodulation
AT gameirosofiar attackingmalignantcellsthatsurvivetherapyexploitingimmunogenicmodulation

Ejemplares similares